|
Developed and refined over seven
years, Hemodyne’s remarkable Hemostasis Analysis System sets a new
standard in platelet and clotting assessment—an advanced level of
diagnosis and control made possible by the system’s unique ability to
supply the “Whole Story.”
The Hemostasis Analysis System offers
the most comprehensive assessment of increased and decreased platelet
activity, as well as clot quality.
In minutes, physicians and
researchers using the HAS can assess bleeding risk, accurately dose and
monitor a wide range of cardiac and blood disorder drugs, assess
cardiovascular risk, and gauge platelet viability.
The Hemostasis Analysis System (HAS)
is the only instrument that provides platelet specific parameters in a
true clotting environment. The HAS performs a completely unique, yet
fundamental assessment that precisely measures the platelet's ability
to retract the clot within the fibrin network.
Other platelet function techniques
provide only ancillary data, often in a simulated or non-clotting
environment, forcing doctors to make broad, indirect interpretations
and diagnoses. Hemodyne's Hemostasis Analysis System (HAS) now paves
the way toward better understanding, diagnosis, and treatment of a
broad array of blood disorders related to clotting factor deficiencies,
surgical complications, and thrombotic risk.
Click
here for more information.
|
